Daily Brief Health Care: Samsung Biologics , HK inno.N, CytoSorbents , Lantheus Holdings, Oryzon Genomics, Symbio Pharmaceuticals and more

• With the Capital Markets Act in place, real-time quotes, intraday fills, and orderbook trading for fractional shares are possible—opening the door for Korea’s Robinhood moment.
• Fractional share trading in Korea is still minimal at 0.1% of volume, but real-time infrastructure from brokers could drive significant flow and growth.
• It will deepen sentiment-driven flows and cause real-time price discovery shifts, opening up new trading opportunities.

• HK inno.N (195940 KS) announced positive topline result from the U.S. Phase 3 trial evaluating K-CAB in gastroesophageal reflux disease. U.S. filing is expected in 4Q25.
• HK inno.N has reported strong 1Q25 result, with double-digit growth across all key parameters. Revenue increased 16% YoY, while operating profit grew at a faster pace of 47% YoY.
• The U.S. filing and approval are the major catalysts. However, HK inno has other growth engines as well. Innovative pipeline is also progressing, ensuring long-term growth prospect.

• CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive care unit and cardiac surgery.
• The company also seeks U.S. and Canadian approval of a second product, DrugSorb-ATR, to reduce perioperative bleeding risk in patients on blood thinners during cardiac surgery.
• Based on the results of its pivotal U.S. and Canadian STAR-T trial, the company submitted for FDA De Novo approval on September 27, 2024, and Health Canada on November 1, 2024, with final regulatory decisions expected in 2025.

• Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics.
• It offers a portfolio of diagnostic & therapeutic products directly & via partnerships & licensing.
• The primary revenue driver is Pylarify, a PET tracer for PSMA-expressing prostate cancer.

Oryzon Genomics has been awarded a €13.26m (US$15m) non-dilutive grant under the Med4Cure initiative, part of the Important Project of Common European Interest (IPCEI) framework, launched in May 2024. As an associate partner, Oryzon will undertake the development of project VANDAM, focused on personalised medicine approaches in rare and orphan diseases. The grant represents c 64% of the €20.68m accepted budget for the 44-month programme and, combined with the €30m recently raised through equity financing, should provide additional financial flexibility to advance Oryzon’s pipeline. The initial focus of the project will be on aggression in subtypes of autism spectrum disorder (ASD) and neuroendocrine tumours, which is strategically aligned with Oryzon’s long-term emphasis on precision medicine in CNS and oncology. We expect to incorporate the grant into our financial model following the Q125 results.

• Sales dropped 55.8% YoY to JPY264mn due to generic competition and inventory adjustments ahead of drug price revision.
• SG&A expenses rose 7.3% YoY to JPY1.4bn, including R&D expenses of JPY819mn, up 18.5% YoY.
• Operating loss was JPY1.2bn, compared to a loss of JPY807mn in Q1 FY12/24, with maintained full-year forecast.